Core Insights - vTv Therapeutics Inc. reported a net loss of $27 million for the full year 2025, with R&D expenses increasing to $17.9 million due to investments in clinical trials for cadisegliatin [1][5] - The company is advancing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes, and has initiated patient dosing in the Phase 3 CATT1 trial [2][5] - A licensing agreement with Newsoara Biopharma Inc. was expanded, granting exclusive worldwide rights to vTv's PDE4 inhibitor, HPP737, for a $20 million upfront payment and potential future milestones totaling up to $115 million plus royalties [3] Financial Performance - vTv Therapeutics reported a net loss of $27 million for 2025 [1][5] - R&D expenses rose to $17.9 million, reflecting increased investment in clinical trials [1] Clinical Development - The company initiated patient dosing in the Phase 3 CATT1 trial and expanded its scientific advisory board with recognized experts [2] - Despite slower-than-expected patient recruitment, vTv increased its clinical site count and engagement efforts, expecting to complete enrollment for the CATT1 trial in Q3 2026 [2] Licensing and Partnerships - An expansion of the licensing agreement with Newsoara Biopharma Inc. was noted, providing exclusive rights to HPP737 in exchange for a $20 million upfront payment and potential future milestones [3] - vTv submitted a Phase 2 clinical study protocol for cadisegliatin to evaluate its efficacy and safety in type 2 diabetes patients, marking a significant step in international research efforts [3]

Core Viewpoint - vTv Therapeutics Inc. is making significant progress in the development of cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, with expectations to complete patient enrollment in the CATT1 Phase 3 trial by the third quarter of 2026 [2][5]. Financial Highlights - The company reported a cash position of $88.9 million as of December 31, 2025, a substantial increase from $36.7 million in the previous year, primarily due to an $80 million financing round [4][8]. - Research and Development (R&D) expenses for the fourth quarter of 2025 were $3.9 million, up from $2.2 million in the same period of 2024, driven by increased spending on cadisegliatin [6][9]. - General and Administrative (G&A) expenses for the fourth quarter of 2025 were $4.0 million, compared to $2.7 million in the fourth quarter of 2024, reflecting higher payroll and legal expenses [9][11]. - The net loss attributable to vTv shareholders for the year ended December 31, 2025, was $27.0 million, or $3.20 per basic share, compared to a net loss of $18.5 million, or $3.20 per basic share, in 2024 [11]. Corporate Developments - In February 2026, vTv received a $20 million upfront payment from Newsoara Biopharma Inc. as part of an amended licensing agreement, which also includes potential future milestone payments totaling up to approximately $115 million [5][12]. - The company has expanded its intellectual property estate supporting cadisegliatin and initiated patient dosing in the Phase 3 CATT1 trial during 2025 [2][5]. - vTv submitted a Phase 2 clinical study protocol for cadisegliatin in type 2 diabetes to the United Arab Emirates Department of Health in December 2025 [5]. Clinical Progress - The CATT1 Phase 3 trial for cadisegliatin has seen slower-than-expected patient enrollment; however, the company has increased the number of participating sites and enhanced engagement efforts, leading to improved enrollment momentum [2][5]. - Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA), indicating its potential as a significant treatment option for type 1 diabetes [12][14].

Group 1: Company Overview - vTv Therapeutics Inc. (NASDAQ:VTVT) is a late-stage biopharmaceutical company focused on developing oral small-molecule drug candidates for diabetes and other chronic diseases [5]. Group 2: Partnership and Financials - On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., transitioning from a regional agreement to a global collaboration for the development of HPP737 [1]. - Under the new terms, Newsoara obtains exclusive worldwide rights to develop and commercialize HPP737, with vTv receiving an immediate $20 million upfront payment and the potential for an additional $115 million in future milestones, along with tiered royalties on net sales [1][4]. Group 3: Product Development - HPP737 is a selective oral therapy aimed at treating inflammation-mediated diseases, such as psoriasis, by inhibiting interleukin-23 and tumor necrosis factor alpha [2]. - Early clinical data indicate that HPP737 is well-tolerated, potentially avoiding common gastrointestinal side effects associated with traditional PDE4 inhibitors, positioning it as a potential best-in-class therapy [2]. Group 4: Strategic Focus - The $20 million influx enhances vTv's balance sheet, allowing the company to concentrate on its primary clinical asset, cadisegliatin, which is currently in Phase 3 trials as a first-in-class oral adjunctive therapy for type 1 diabetes [4]. - By leveraging Newsoara's development capabilities for HPP737, vTv can prioritize its late-stage diabetes pipeline while maintaining a diversified source of long-term value through global milestones and royalties [4].

Core Insights - vTv Therapeutics has expanded its license agreement with Newsoara Biopharma, granting Newsoara global rights to develop and commercialize the PDE4 inhibitor HPP737, which is aimed at treating inflammation-mediated diseases [1][3] - The agreement includes an upfront payment of $20 million, potential future development milestones of approximately $50 million, sales milestones of up to $65 million, and tiered royalties based on net sales [2][3] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for chronic diseases, particularly type 1 diabetes [8] - The company's lead product, cadisegliatin, is currently in a Phase 3 trial and has received Breakthrough Therapy designation from the FDA [6][8] Product Details - HPP737 is a selective phosphodiesterase type 4 (PDE4) inhibitor that has shown therapeutic activity in animal models of inflammation and has been well tolerated in phase 1 studies [3][4] - The drug aims to address unmet needs in inflammation-mediated diseases and may avoid gastrointestinal side effects commonly associated with other PDE4 inhibitors [4] Strategic Collaboration - The collaboration with Newsoara is seen as a strategic priority for vTv, enhancing its balance sheet and providing a significant source of potential value creation for shareholders [2][3] - Newsoara plans to leverage its development and commercialization capabilities to advance HPP737 and bring it to patients worldwide [3][9]

Core Viewpoint - vTv Therapeutics Inc. has announced a Phase 2 clinical study for cadisegliatin, an oral adjunctive therapy to insulin for type 2 diabetes, in collaboration with M42's Insights Research Organization & Solutions [1][2] Group 1: Clinical Study Details - The Phase 2 study protocol has been submitted to the Department of Health Abu Dhabi and aims to evaluate the safety and efficacy of cadisegliatin over a 12-month period [1] - The trial will enroll approximately 300 patients with type 2 diabetes who are treated with insulin, randomized into three groups: two cadisegliatin dose groups (400 mg and 800 mg once daily) and a placebo control group [1] - The trial will take place in the UAE, Jordan, and Tunisia, with the first patient visit expected in Q1 2026 [1] Group 2: Company and Product Information - Cadisegliatin (TTP399) is a novel oral small molecule being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes and has received Breakthrough Therapy designation from the FDA [4][6] - vTv Therapeutics is focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin leading its clinical pipeline [6] Group 3: Collaboration and Market Potential - The collaboration with M42 allows vTv to expand the geographic footprint for cadisegliatin, targeting populations with high prevalence of type 2 diabetes, particularly in the UAE [2][3] - IROS, as the funding partner for the study, aims to leverage its expertise in clinical research to potentially impact the lives of millions with type 2 diabetes [3][7]

Core Insights - vTv Therapeutics is advancing its cadisegliatin program, a potential first-in-class oral adjunctive therapy for type 1 diabetes, with topline Phase 3 CATT1 data expected in the second half of 2026 [1][2] - The company successfully completed an $80 million private placement to strengthen its balance sheet and support the ongoing Phase 3 trial [1][5] - A new U.S. patent covering crystalline salts and co-crystals of cadisegliatin has been issued, providing exclusivity until 2041 [1][5] Recent Company Highlights - The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025 [5] - The patent allowance for cadisegliatin's crystalline salt form was granted by the U.S. Patent and Trademark Office [5] - The cash position as of September 30, 2025, was $98.5 million, a significant increase from $36.7 million as of December 31, 2024 [5][7] Third Quarter 2025 Financial Results - Research and Development (R&D) expenses increased to $7.0 million in Q3 2025 from $3.2 million in Q3 2024, reflecting higher spending on cadisegliatin and other projects [5][9] - General and Administrative (G&A) expenses rose to $3.7 million in Q3 2025 from $3.3 million in Q3 2024, primarily due to payroll and legal expenses [5][9] - The net loss attributable to vTv shareholders for Q3 2025 was $8.7 million, or $1.08 per basic share, compared to a net loss of $4.8 million, or $0.88 per basic share, in the same period last year [5][10]

Core Insights - vTv Therapeutics has appointed a distinguished Scientific Advisory Board (SAB) to guide the clinical development of cadisegliatin for type 1 diabetes, which is currently in Phase 3 trials [1][2][4] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin as its lead candidate [7] Scientific Advisory Board - The SAB includes experts in endocrinology and diabetes research, such as Dr. John Buse, Dr. Alfonso Galderisi, Dr. Mark Evans, Dr. Chantal Mathieu, Dr. Alexander Fleming, and Dr. Klara Klein, who will provide strategic guidance on clinical trial planning and regulatory strategy [2][8] Cadisegliatin Details - Cadisegliatin (TTP399) is a novel oral small molecule that acts as a liver-selective glucokinase activator, being investigated as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes [5][6]

Core Insights - vTv Therapeutics Inc. is presenting new independent research on its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the EASD 61 Annual Meeting [1][2] - The company is focusing on TTP-RA, an oral RAGE antagonist, and cadisegliatin, a potential first-in-class oral glucokinase activator, both aimed at improving T1D treatment [3][4] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company dedicated to developing oral, small molecule drug candidates for diabetes and other chronic diseases [4] - The clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial for T1D [4][5] Research and Development - Dr. Carmen Valcarce will present preclinical data on TTP-RA, highlighting its ability to restore glucose homeostasis and modulate immune responses [2][3] - The company is actively seeking strategic partnerships to advance the development of TTP-RA [2][4] Product Details - Cadisegliatin (TTP399) is being investigated as a potential first-in-class oral adjunctive treatment for T1D, showing increased glucokinase activity in non-clinical studies [5]

Core Insights - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment [1][2] - The company will participate in two upcoming investor conferences in September 2025, including the H.C. Wainwright 27th Annual Global Investment Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference [1][2] Company Overview - vTv Therapeutics specializes in oral, small molecule drug candidates aimed at treating diabetes and other chronic diseases [2] - The clinical pipeline is led by cadisegliatin, which is currently in a Phase 3 trial as a potential oral glucokinase activator for type 1 diabetes [2] - The company is also exploring multiple molecules across various indications for chronic diseases in collaboration with development partners [2]

Company Overview - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes [1][2] - The company is also investigating multiple molecules across different indications for chronic diseases [2] Upcoming Investor Conferences - vTv Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with a format of 1x1 investor meetings only [1] - The company will also be present at the Morgan Stanley 23rd Annual Global Healthcare Conference on the same day, featuring a fireside chat from 2:35 PM to 3:10 PM EST, along with 1x1 investor meetings [2] Clinical Pipeline - The clinical pipeline of vTv is led by cadisegliatin, which is currently in a Phase 3 trial for type 1 diabetes [2]